Dicarbonyls and Glyoxalase in Disease Mechanisms and Clinical Therapeutics
Total Page:16
File Type:pdf, Size:1020Kb
Glycoconj J DOI 10.1007/s10719-016-9705-z REVIEW Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics Naila Rabbani1 & Mingzhan Xue2 & Paul J. Thornalley1,2 Received: 28 February 2016 /Revised: 6 June 2016 /Accepted: 9 June 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract The reactive dicarbonyl metabolite methylglyoxal responsive increase of Glo-1 expression. Small molecule Glo- (MG) is the precursor of the major quantitative advanced 1 inducers are in clinical development for improved metabolic, glycation endproducts (AGEs) in physiological systems - argi- vascular and renal health and Glo-1 inhibitors in preclinical nine-derived hydroimidazolones and deoxyguanosine-derived development for multidrug resistant cancer chemotherapy. imidazopurinones. The glyoxalase system in the cytoplasm of cells provides the primary defence against dicarbonyl glycation Keywords Methylglyoxal . Glycation . Glyoxalase . by catalysing the metabolism of MG and related reactive Obesity . Diabetes, cancer . Renal failure . Cardiovascular dicarbonyls. Dicarbonyl stress is the abnormal accumulation disease . Therapeutics of dicarbonyl metabolites leading to increased protein and DNA modification contributing to cell and tissue dysfunction in ageing and disease. It is produced endogenously by increased Abbreviations formation and/or decreased metabolism of dicarbonyl metabo- ADH Aldehyde dehydrogenase lites. Dicarbonyl stress contributes to ageing, disease and activ- AGE Advanced glycation endproduct ity of cytotoxic chemotherapeutic agents. It contributes to age- AKR Aldoketo reductase ing through age-related decline in glyoxalase 1 (Glo-1) activity. ARE Antioxidant response element Glo-1 has a dual role in cancer as a tumour suppressor protein CVD Cardiovascular disease prior to tumour development and mediator of multi-drug resis- 3-DG 3-Deoxyglucosone tance in cancer treatment, implicating dicarbonyl glycation of DHAP Dihydroxyacetonephosphate DNA in carcinogenesis and dicarbonyl-driven cytotoxicity in ESRD End stage renal disease mechanism of action of anticancer drugs. Glo-1 is a driver of GA3P Glyceraldehyde-3-phosphate cardiovascular disease, likely through dicarbonyl stress-driven GdG 3-(2′-deoxyribosyl)-6,7-dihydro-6,7- dyslipidemia and vascular cell dysfunction. Dicarbonyl stress is dihydroxyimidazo-[2,3-b]purin-9(8)one also a contributing mediator of obesity and vascular complica- Glo-1 Glyoxalase 1 tions of diabetes. There are also emerging roles in neurological HFD High fat diet disorders. Glo-1 responds to dicarbonyl stress to enhance HIF1α Hypoxia-inducible factor-1α cytoprotection at the transcriptional level through stress- HSP27 Heat shock protein 27 MDR Multidrug resistance MG Methylglyoxal * Paul J. Thornalley ′ [email protected] MGdG 3-(2 -deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6/ 7-methylimidazo-[2,3-b]purine-9(8)one 1 Warwick Systems Biology Centre, Coventry House, University of MG-H1 Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine Warwick, Coventry CV4 7AL, UK NAFLD Non-alcoholic fatty liver disease – 2 Glyoxalase Research Group, Clinical Sciences Research Nrf2 Nuclear factor erythroid 2 related factor 2 Laboratories, Warwick Medical School, University of Warwick, PBMC Peripheral blood mononuclear cells University Hospital, Coventry CV2 2DX, UK RAGE Receptor for advanced glycation endproducts Glycoconj J ROS Reactive oxygen species glyceraldehyde-3-phosphate (GA3P) and SSAO Semicarbazide amine oxidase dihydroxyacetonephosphate (DHAP) - 0.05 – 0.1 % of flux. T2DM Type 2 diabetes mellitus GA3P was ca. 8-fold more reactive than DHAP in degrading to MG but as the concentration ratio of DHAP/GA3P in cells in situ is ca. 9orsimilar[9], both of these triosephosphates are Dicarbonyl stress and the glyoxalase system important sources of MG formation in physiological systems in situ [10]. MG formation is a minor fate of triosephosphates: Dicarbonyl stress is the abnormal accumulation of dicarbonyl early studies with red blood cells suggested only 0.089 % metabolites leading to increased modification of protein and glucotriose (2 x glucose consumption) was converted to MG DNA contributing to cell and tissue dysfunction in ageing and [11] and our subsequent studies with endothelial cells and disease [1]. Highly reactive dicarbonyl metabolites often mediat- fibroblasts suggest a similar flux. The rate of total cellular ing dicarbonyl stress in physiological systems are methylglyoxal formation of MG was estimated to be ca. 125 μmol/kg cell (MG), glyoxal, 3-deoxyglucosone (3-DG) and others. The mass per day [11], which for an adult human of 70 kg body glyoxalase system is a cytoplasm enzymatic pathway, which mass and 25 kg body cell mass [12] equates to a predicted metabolises the most highly reactive acyclic dicarbonyls – main- whole body rate of formation of ca. 3mmolMGperday(or ly MG and glyoxal. It thereby plays a major role in suppressing ca. 3 mg/kg body weight/day). MG is also formed by the dicarbonyl stress in physiological systems, keeping dicarbonyl oxidation of acetone catalysed by cytochrome P450 2E1 in metabolites at low, tolerable levels. Typical concentrations of the catabolism of ketone bodies [13] – which is low except glyoxal and MG are 50–150 nM in human plasma and 1– where ketone bodies are increased as in diabetic ketoacidosis, 4 μM in plant and mammalian cells [2–4]. When dicarbonyl prolonged (>3 days) fasting or low calorie diet [13–15]. MG concentrations increase beyond this there is potential for protein may also be formed from the oxidation of aminoacetone by and cell dysfunction leading to impaired health and disease. semicarbazide amine oxidase (SSAO) in the catabolism of Examples of dicarbonyl stress are the increased MG in ageing threonine [16]. Recent estimates of the concentration and rates plants [2], increased MG-protein modification in ageing human of metabolism of aminoacetone in the presence and absence of lens [5], increased plasma and tissue concentration of MG in SSAO inhibitor suggest this pathway has a flux of ca. diabetes [6], and increased concentrations of MG and glyoxal 0.1 mmol MG per day in human subjects [17]orca. 3%of in renal failure [4]. Dicarbonyl stress is caused by an imbalance total MG formation. Vascular adhesion protein-1 is considered of the formation and metabolism of dicarbonyl metabolites and the origin of SSAO activity in mammals in vivo [18]. It is also by increased exposure to exogenous dicarbonyls – Fig. 1a. found in plasma, endothelium, adipose tissue and smooth In this review there is a particular but not exclusive focus on MG muscle and increases ca. 2-fold in congestive heart failure, as it is a major contributor to dicarbonyl stress in physiological diabetes and inflammatory liver diseases [19], and may relat- systems. Other recent reviews focussing mostly on dicarbonyl edly increase MG formation in these conditions. MG is also stress in obesity and diabetes have been given elsewhere [7, 8]. formed by the degradation of proteins glycated by glucose and the degradation of monosaccharides [20]. Under physiological conditions with low level phosphate and chelation of trace Formation of methylglyoxal metal ion, the predicted flux of MG formation from glycated protein degradation is ca. 0.2 mmol MG per day or ca. 7%of In mammalian metabolism, MG is formed at relatively high total MG formation. Dietary contributions to MG exposure flux mainly by the trace level degradation of triosephosphates, from food are normally relatively low: sweetened soft drink, Fig. 1 Biochemistry of dicarbonyl stress. a Metabolism of MG by the glyoxalase system. b Formation of hydroimidazolone MG-H1 from arginine residues. c Formation of imidazopurinone MGdG in DNA. Adduct residue is shown with guanyl base only Glycoconj J 330 ml – 0.1 μmol MG [21], fruit juice, 330 ml – 0.7 μmol, abundance in human cells [29]. In principle, ADHs may also bread/cakes, 100 g, 1–2 μmol and other foodstuffs [22]; that metabolise glyoxal and MG to glyoxylate and pyruvate, re- is, combined likely <0.03 mmol MG per day or <1 % MG spectively. In examination of ADH-linked MG dehydroge- exposure. MG in foodstuffs was also metabolised and/or nase activity in human cells to date we have found very low reacted with proteins before absorption in the gastrointestinal or undetectable activity. AKRs and ADH catalyse the metab- tract and imposed dicarbonyl stress mainly in the gastrointes- olism of 3-DG whereas Glo-1 does not [4, 30]. Other proteins, tinal lumen [23]. The diet may contribute markedly greater to Bglyoxalase III^ and DJ1, were proposed as glyoxalases but total exposure for other dicarbonyls where culinary heating is their low catalytic efficiency and cellular content suggests this a source of formation; for example, 3-DG [24]. Sources of is unlikely [31]. formation of MG and routes of metabolism are summarised Basal and inducible expression of Glo-1, AKRs and ADH in Fig. 2. are under stress-responsive control by nuclear factor erythroid 2–related factor 2 (Nrf2) through regulatory antioxidant re- sponse elements (AREs) [32–36].Thecytoprotectivefunction Dicarbonyl metabolism by the glyoxalase system of Nrf2 therefore involves enhancing basal and inducible ex- pression and activities of enzymes of dicarbonyl metabolism Glyoxal and MG are metabolised mainly by glyoxalase 1 and thereby prevention of dicarbonyl stress [32]. Other regu- (Glo-1) of the glutathione-dependent glyoxalase system, with latory elements in the mammalian GLO-1